Research and Markets: Commercial Insight: Cardiovascular and Metabolic Market Overview Diabetes to the Fore as Generics Hit Primary Care Markets

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/80e15a/commercial_insight) has announced the addition of the "Commercial Insight: Cardiovascular and Metabolic Market Overview Diabetes to the Fore as Generics Hit Primary Care Markets" report to their offering.

“Commercial Insight: Cardiovascular and Metabolic Market Overview Diabetes to the Fore as Generics Hit Primary Care Markets”

Antidiabetic therapies is expected to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Scope

• A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.
• An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.
• Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017.

Key Topics Covered:

• CHAPTER 1 EXECUTIVE SUMMARY 3
• CHAPTER 2 MARKET OVERVIEW AND DYNAMICS 8
• CHAPTER 3 MARKET FORECASTS 57
• CHAPTER 4 MARKET ANALYSIS 108
• APPENDIX A - MARKET ASSUMPTIONS 137
• APPENDIX B -MARKET FORECAST DATA 140
• APPENDIX C 224
• List of Tables
• List of Figures

For more information visit http://www.researchandmarkets.com/research/80e15a/commercial_insight

Source: Datamonitor